Gene Expression Profiles of Breast Cancer Treated With Sequential Adriamycin and Docetaxel in Relation to Tumor Responses
Significant inter-individual variation exists in tumor response and chemotherapy toxicity
because of unique tumor and patient factors. Individual drugs with distinct mechanisms of
action may induce specific genomic and proteomic changes that may be used as predictor for
response. We plan to study serial genomic and proteomic profiles in primary breast tumor
treated with one of two sequences of alternating adriamycin (A) and docetaxel (T),
A>T>A>T>A>T, or T>A>T>A>T>A, at 75mg/m2 3 weekly for each drug. Pharmacokinetic analysis of
both drugs will be performed; amplified tumor RNA will be hybridized on Affymetrix®
HG-U133+2 array; tumor proteins will be fractionated and profiled with ProteinChip® Array
SELDI MS (Ciphergen). Tumor gene expression and proteomic changes will be correlated with
treatment response to identify biomarkers that may predict chemotherapy sensitivity.
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
1. Evaluate the impact of adriamycin and docetaxel on tumor gene expression profiles.
Soo-Chin Lee, MD
Singapore: Health Sciences Authority